414,600 Shares in Exact Sciences Corporation $EXAS Bought by Braidwell LP

Braidwell LP purchased a new position in shares of Exact Sciences Corporation (NASDAQ:EXAS) in the third quarter, according to its most recent filing with the SEC. The firm purchased 414,600 shares of the medical research company’s stock, valued at approximately $22,683,000. Braidwell LP owned 0.22% of Exact Sciences at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in EXAS. Ameriprise Financial Inc. lifted its stake in shares of Exact Sciences by 105.8% in the 3rd quarter. Ameriprise Financial Inc. now owns 4,493,085 shares of the medical research company’s stock valued at $245,802,000 after purchasing an additional 2,310,139 shares during the period. Massachusetts Financial Services Co. MA grew its stake in Exact Sciences by 31.7% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,909,501 shares of the medical research company’s stock worth $213,889,000 after purchasing an additional 939,888 shares during the period. William Blair Investment Management LLC increased its holdings in Exact Sciences by 26.5% in the third quarter. William Blair Investment Management LLC now owns 2,555,051 shares of the medical research company’s stock worth $139,787,000 after purchasing an additional 534,881 shares in the last quarter. Champlain Investment Partners LLC lifted its stake in Exact Sciences by 12.6% in the second quarter. Champlain Investment Partners LLC now owns 2,529,820 shares of the medical research company’s stock valued at $134,435,000 after buying an additional 282,825 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Exact Sciences by 12.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,188,864 shares of the medical research company’s stock worth $119,732,000 after buying an additional 239,313 shares in the last quarter. 88.82% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on EXAS. TD Cowen lowered shares of Exact Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday, November 25th. Guggenheim cut shares of Exact Sciences from a “buy” rating to a “neutral” rating in a report on Thursday, November 20th. William Blair cut Exact Sciences from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 20th. Canaccord Genuity Group downgraded Exact Sciences from a “buy” rating to a “hold” rating and boosted their price objective for the company from $85.00 to $105.00 in a report on Tuesday, November 25th. Finally, Leerink Partners lowered Exact Sciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 20th. Twenty-one investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Exact Sciences has an average rating of “Reduce” and a consensus target price of $92.13.

Exact Sciences Trading Up 0.3%

EXAS opened at $103.57 on Friday. Exact Sciences Corporation has a fifty-two week low of $38.81 and a fifty-two week high of $103.75. The firm has a market capitalization of $19.77 billion, a PE ratio of -94.15, a P/E/G ratio of 2.36 and a beta of 1.41. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.43 and a quick ratio of 2.17. The company’s 50-day moving average is $102.83 and its 200 day moving average is $83.86.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings results on Friday, February 13th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.29). Exact Sciences had a negative net margin of 6.40% and a positive return on equity of 0.53%. The business’s revenue was up 23.1% on a year-over-year basis. During the same period last year, the company posted ($0.06) EPS. As a group, research analysts predict that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

About Exact Sciences

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.